SESSION III: THE SPECIALTY PHARMACEUTICALS MARKETPLACE: IS PRICE - PowerPoint PPT Presentation

SESSION III: THE SPECIALTY PHARMACEUTICALS MARKETPLACE: IS PRICE INELASTICITY SUSTAINABLE?

Headlines “Exclusive Costs to public of $84,000 hp C Drug outreageous- Kaiser.” http://www.reuters.com/article/2014/04/02/us-hepatitisc-gilead-sciences- idUSBREA311Y120140402, accessed 2/9/2015 “ $1,000 Pill For Hepatitis C Spurs Debate Over Drug Prices ” http://www.npr.org/blogs/health/2013/12/30/256885858/-1-000-pill-for-hepatitis-c- spurs-debate-over-drug-prices. Published December 30,2013, accessed 2/10/2015.

The Rise of Specialty Pharmaceuticals Expected to be 50% of pharmaceutical spending by 2019 Pharmaceutical spending grew by 13.1% in 2014 to $374 Billion. Source: http://www.nytimes.com/interactive/2013/03/19/business/for-some-spending-less-on-drugs.html

Specialty Pharmaceuticals Hirsch, Bradford R., Suresh Balu, and Kevin A. Schulman. "The Impact Of Specialty Pharmaceuticals As Drivers Of Health Care Costs." Health Affairs 33.10 (2014): 1714-1720.

Rise of Personalized Medicine Population and Personalized Medicine in the Modern Era JAMA. 2014;312(19):1969-1970. doi:10.1001/jama.2014.15224

Personalized Medicine: BRAF V600E Mutation Chapman, Paul B., et al. "Improved survival with vemurafenib in melanoma with BRAF V600E mutation." New England Journal of Medicine 364.26 (2011): 2507-2516.

PCSK9 and Cardiovascular Disease Sabatine MS et al. N Engl J Med 2015;372:1500-1509; Robinson JG et al. N Engl J Med 2015;372:1489-1499.

Specialty Pharmaceuticals 150 120 90 60 30 Hirsch, Bradford R., Suresh Balu, and Kevin A. Schulman. "The Impact Of Specialty Pharmaceuticals As Drivers Of Health Care Costs." Health Affairs 33.10 (2014): 1714-1720.

Economics Warden, 2005

Panel Discussion MODERATOR Kevin Schulman Duke University PANEL Justin Klein NEA Richard Evans Head of Healthcare Practice SSR LLC Sean Tunis Center for Medical Technology Policy Julie Stoss Kaiser Permanente